Fri, May 29, 2009
Thu, May 28, 2009
Wed, May 27, 2009
Tue, May 26, 2009
Mon, May 25, 2009
Fri, May 22, 2009
Thu, May 21, 2009
Wed, May 20, 2009
Tue, May 19, 2009
Mon, May 18, 2009
Fri, May 15, 2009
Thu, May 14, 2009
Wed, May 13, 2009
Tue, May 12, 2009
Mon, May 11, 2009
Fri, May 8, 2009
Thu, May 7, 2009
Thu, April 16, 2009
Wed, April 15, 2009
Tue, April 14, 2009
Mon, April 13, 2009
Fri, April 10, 2009
Thu, April 9, 2009
Wed, April 8, 2009
Tue, April 7, 2009
Mon, April 6, 2009
Fri, April 3, 2009
Thu, April 2, 2009
Wed, April 1, 2009
Tue, March 31, 2009
Mon, March 30, 2009
Fri, March 27, 2009
Thu, March 26, 2009
Wed, March 25, 2009
Tue, March 24, 2009
Mon, March 23, 2009
Fri, March 20, 2009
Thu, March 19, 2009
Wed, March 18, 2009
Tue, March 17, 2009
Mon, March 16, 2009
Sun, March 15, 2009
Fri, March 13, 2009
Thu, March 12, 2009
Wed, March 11, 2009
Tue, March 10, 2009
Mon, March 9, 2009
Fri, March 6, 2009
Thu, March 5, 2009
Wed, March 4, 2009
Tue, March 3, 2009
Mon, March 2, 2009
Fri, February 27, 2009
Thu, February 26, 2009

Clearant, Inc.: Clearant, Inc. Reports Record 2008 Revenue Results


//health-fitness.news-articles.net/content/2009/ .. ant-inc-reports-record-2008-revenue-results.html
Published in Health and Fitness on Wednesday, April 1st 2009 at 15:01 GMT, Last Modified on 2009-04-01 15:02:10 by Market Wire   Print publication without navigation


LOS ANGELES, CA--(Marketwire - April 1, 2009) - Clearant, Inc. (OTCBB: [ CLRA ]), owner of the Clearant Process® which is designed to substantially reduce all types of pathogens in biological products, including HIV, today announced that revenues for the twelve months ended December 31, 2008 increased 74% to a record $1.88 million compared to $1.08 million for the twelve months ended December 31, 2007.

Direct distribution revenue increased 129% to a record $1.60 million for the twelve months ended 2008, compared to $0.70 million for the twelve months ended 2007. Revenues from licensing, fee for service, and contract research activities which the Company has been de-emphasizing, decreased to $284,000 for the twelve months ended December 31, 2008 from $388,000 for the twelve months ended December 31, 2007.

Revenues for the 4th quarter ended December 31, 2008 increased 41% to $0.45 million compared to $0.32 million for the 4th quarter ended December 31, 2007.

Direct distribution revenue increased 62% to $0.42 million for the 4th quarter ended December 31, 2008 compared to $0.26 million in the 4th quarter ended December 31, 2007. Revenues from licensing, fee for service, and contract research activities increased to $36,000 in the 4th quarter ended December 31, 2008 compared to $65,000 in the 4th quarter ended December 31, 2007.

More detailed information about Clearant's 2008 results can be found in its Annual Report filed with the Securities and Exchange Commission on March 24, 2009.

About Clearant, Inc.

Clearant, Inc. is a leader in pathogen inactivation for biological products. Clearant has developed the patent-protected Clearant Process®, which substantially reduces all types of bacteria and viruses in biological products while maintaining the functionality of the underlying tissue implant or protein. The Company has distributed implants sterilized by the Clearant Process® directly to surgeons, hospitals and clinics since June 2006. In addition, Clearant licenses the Clearant Process®, and provides its patented sterilization services, to tissue banks and other biological products manufacturers. To date more than 8,000 patients have been successfully implanted with Clearant Process® sterile implants supplied by one of the Company's licensed partners. The Clearant Process®, unlike its various competitors, is applied in the final packaging and reduces all types of pathogens for products across many market segments including tissue implants, plasma proteins, recombinant products, medical devices and blood products. For more information, please visit [ www.clearant.com ].

Forward-Looking Statements

Except for statements of historical fact, the matters discussed in this press release are forward-looking and made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond the company's control that may cause actual results to differ materially from stated expectations. These risk factors include, among others, limited financial resources and difficulty in developing and exploiting proprietary technologies and additional risk factors as discussed in the reports filed by the Company with the Securities and Exchange Commission, which are available on its website at [ http://www.sec.gov ].


Publication Contributing Sources

Similar Health and Fitness Publications